Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
qpRNzg8NB6a3e4HB
Listen
